Tamoxifen Teva

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Tamoxifen Teva

Property Description
Active Ingredient Tamoxifen (as Tamoxifen Citrate)
Form Oral Tablet (Film-coated)
Pharmacological Class Selective Estrogen Receptor Modulator (SERM); Antineoplastic Agent
Common Use Targeted hormone-related treatment
Origin Synthetic

What Type of Medicine is Tamoxifen Teva?

Tamoxifen Teva is a prescription-only medicine containing the active substance Tamoxifen, a synthetic, non-steroidal compound. The preparation is supplied as an oral tablet for systemic administration and is manufactured by Teva, a globally recognized pharmaceutical entity. It is a single-ingredient product classified as an Antineoplastic Agent, signifying its role in specific cancer therapies.

The Tamoxifen compound is widely recognized for its clinical importance. Tamoxifen is included on the Model List of Essential Medicines, confirming its established role in global health systems. This international recognition underscores that Tamoxifen is a verified, core component for its intended therapeutic purpose.

Tamoxifen Teva’s Pharmacological Classification and Purpose

The primary classification for Tamoxifen is a Selective Estrogen Receptor Modulator (SERM), a specialized designation utilized by major regulatory bodies. Its general purpose is to control the influence of the hormone estrogen on certain hormone-sensitive cellular processes.

The mechanism relies on a targeted hormone blockade: Tamoxifen acts as an antiestrogen in specific tissues, binding to the estrogen receptors to inhibit the growth signals that natural estrogen would otherwise transmit. Pharmacological studies confirm that this unique action allows Tamoxifen to function as a cytostatic agent that helps stabilize and manage disease progression by interfering with specific hormonal pathways.

Regulatory References

  1. World Health Organization (WHO)
  2. MedlinePlus Monograph
Advertisements

What side effects are possible with Tamoxifen Teva?

Possible side effects and safety information

The safety profile of Tamoxifen Teva is based on comprehensive data from regulatory authorities, categorizing potential effects by frequency and the body system affected. Adverse reactions are grouped by the official frequency framework (Very Common, Common, Uncommon, Rare).

Adverse Reaction Classification

Frequency Classification Examples of Officially Documented Adverse Reactions
Very Common (ge 1/10) Hot flashes, fluid retention, nausea, vaginal bleeding or discharge.
Common (ge 1/100 to <1/10) Fatigue, headache, skin rash, cataracts, endometrial changes (e.g., hyperplasia), and thromboembolic events (including deep vein thrombosis).
Uncommon (ge 1/1,000 to <1/100) Endometrial cancer, pancreatitis.
Rare (ge 1/10,000 to <1/1,000) Severe liver disorders (e.g., liver failure, cholestasis), optic neuropathy.

Serious Adverse Reactions and Safety Constraints

The official labeling documents certain risks as serious, although they may occur uncommonly or rarely. These include thromboembolic events (Deep Vein Thrombosis, Pulmonary Embolism) and the risk of uterine malignancy (Endometrial Cancer, Uterine Sarcoma).

Duration-Related Safety: The development of endometrial cancer and certain ocular changes are specifically noted in regulatory documents as being associated with long-term exposure to tamoxifen.

Population-Specific Notes: The occurrence of reversible ovarian cysts is commonly noted in pre-menopausal women. Use is restricted in patients with a history of thromboembolic disease due to the recognized risk of recurrence.

Advertisements

Overdose and Emergency Response

Tamoxifen Teva Overdose and when to seek help

Overdose Scope

Documented overdose presentations derived from official regulatory information include acute Central Nervous System (CNS) manifestations. These signs typically involve uncontrollable shaking of a part of the body, general unsteadiness, and dizziness. In high-dose scenarios, official literature has also associated overexposure with QT interval prolongation, which is a potential cardiac effect.

When Immediate Medical Help Is Required (Label-Derived Phrasing Only)

Immediate medical attention is officially required for severe or life-threatening indicators. Regulator-mandated guidance states that emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, is showing trouble breathing, or cannot be awakened. The national poison control helpline is the required contact for initial guidance.

Overdose Classifications (High-Level)

The severity classification distinguishes between minor CNS signs and severe, life-threatening outcomes that necessitate hospitalization. The regulatory basis for treatment is constrained by the fact that no specific antidote is known for Tamoxifen. Consequently, the official management protocol is defined as strictly symptomatic and supportive treatment provided by medical professionals.

Resulting Overdose Structure: Official Overdose Statements

  • Documented symptoms affect CNS and motor function, including shaking, dizziness, and unsteadiness.
  • Life-threatening outcomes that mandate urgent medical services include collapse, seizure, and respiratory distress.
  • The official management framework confirms that no specific antidote is known, requiring strictly symptomatic care.

Connection to the Overall Overdose Profile

Official regulatory documents define the overdose profile through specific symptom clusters and explicit triggers for seeking emergency services, ensuring appropriate medical response to potential acute exposures.

Advertisements

Therapeutic Uses of Tamoxifen Teva

Tamoxifen Teva is commonly used to provide long-term support in situations where disease processes are primarily driven by the hormone estrogen. This medication is associated with targeted, hormone-related treatment. This medicine is relevant for use in conditions where symptoms may intensify temporarily.

Tamoxifen Teva is commonly applied in clinical settings that involve Estrogen Receptor-Positive (ER+) breast cancer, including both early-stage and advanced manifestations. It is used to help manage or suppress the progression of hormone-sensitive tumors in both premenopausal and postmenopausal women, as well as men. It is relevant for managing the risk of cancer recurrence and the risk of a new primary cancer. It is relevant in situations requiring long-term assistance in symptom stabilization.

Beyond oncology, the medication is applied across domains where additional symptomatic support is needed. It is used to help with symptoms related to localized breast pain and tenderness associated with benign hormonal breast enlargement, such as gynecomastia in male patients. This use is relevant for easing discomfort, which supports general well-being during symptomatic phases.


Quick Fact: Support for Symptom Manifestations Tamoxifen Teva may assist with easing discomfort and tenderness associated with benign hormonal breast enlargement in male patients, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tamoxifen Teva — Official Regulatory Information

The official eligibility profile for Tamoxifen Teva is defined by specific criteria from governmental regulatory bodies.


Populations for Whom Use is Allowed

The medicine is generally approved for use in Adult Females (pre- and postmenopausal) and Adult Males. Use is also approved for girls aged 2-10 for specific pediatric conditions, though its safety and efficacy for the general pediatric population have not been fully established.


Populations for Whom Use is Contraindicated

Use is strictly contraindicated in patients with a known hypersensitivity to the drug or any of its ingredients. It is also contraindicated in pregnancy due to the risk of fetal harm, and women of childbearing potential are required to use effective non-hormonal contraception.


Eligibility-Related Restrictions

For the risk reduction setting (in women at high risk or with DCIS), the medicine is contraindicated if the patient has a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), or if they require concomitant use of the anticoagulant warfarin. Use is not recommended for breastfeeding women as the drug is excreted into breast milk. Caution is advised for patients with reduced liver function as definitive data on metabolism in this population are limited.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information highlights several drug and substance interactions that may affect the systemic exposure or combined effects of Tamoxifen. These documented patterns establish specific constraints for co-administration.


Medicinal Product Restrictions

Classification Interacting Agents (Examples) Official Constraints (Summary)
Contraindicated Aromatase Inhibitors (e.g., Anastrozole) Formal restriction against co-administration, as regulatory data indicates no added benefit and Tamoxifen reduces the concentration of the co-administered drug.
Contraindicated Coumarin-type Anticoagulants (e.g., Warfarin) Avoidance is required in patients with a history of deep vein thrombosis or pulmonary embolism due to an enhanced anticoagulant effect and increased bleeding risk.
Major Risk Strong CYP2D6 Inhibitors (e.g., Paroxetine, Fluoxetine) Co-administration is advised against, as it significantly reduces the concentration of the active metabolite, Endoxifen.

Exposure and Risk Modification

  • CYP3A4 Induction: Agents like Rifampin are documented to reduce Tamoxifen's overall plasma exposure ( AUC and C max), necessitating caution due to reduced drug levels.
  • Thrombotic Risk: Co-administration with certain Cytotoxic Chemotherapy Agents is documented in regulatory labeling to increase the incidence of thromboembolic events.
  • Herbal and Food Products: The herbal product St. John’s Wort may reduce blood levels of Tamoxifen due to enzyme induction. The consumption of alcohol should also be limited or avoided as it may decrease the medicine’s efficacy.

Official prescribing information notes that individuals who are CYP2D6 Poor Metabolizers exhibit naturally lower concentrations of Endoxifen, consistent with reduced metabolic activation.

Advertisements

Mechanism of Action

Tamoxifen is a nonsteroidal agent that functions as a Selective Estrogen Receptor Modulator (SERM). Its action is mediated by the estrogen receptor (ER), to which it and its active metabolites, primarily endoxifen, bind competitively with endogenous estrogens.

This binding induces a conformational change in the ER complex. In tissue-specific contexts, such as the mammary epithelium, the tamoxifen-ER complex recruits co-repressor proteins, resulting in the inhibition of estrogen-responsive gene transcription. This pathway modulation leads to a block in the cell cycle, primarily in the G0/G1 phases, classifying the effect as cytostatic.

Conversely, in other tissues, such as bone, the drug-receptor interaction may recruit co-activator proteins, resulting in an estrogen-like agonist effect on gene expression. The final physiological consequence of its selective action depends on the specific target cell's expression profile of co-regulator proteins.

Advertisements

Dosage and Administration Information

How to Use Tamoxifen Teva

Tamoxifen Teva is an oral medicine, meaning it is administered by mouth for systemic absorption. The tablets, which are available in strengths of 10 mg and 20 mg, are intended to be swallowed whole with liquid and must not be crushed, chewed, or split.


Official Dosing and Scheduling

The standard prescribed daily dose for most adults typically ranges from 20 mg to 40 mg. The 20 mg dose is commonly taken once daily. If the total daily dose is higher, such as 40 mg, the administration is typically divided into two separate doses, usually taken in the morning and the evening. For consistency in blood levels, the medicine should be consumed at approximately the same time each day, and intake is permitted with or without food.


Course Duration and Dose Management

Treatment with Tamoxifen is often a long-term protocol, with the officially recognized duration for adjuvant and risk-reduction regimens typically being five years, though treatment may extend up to ten years in certain contexts.

If a dose is missed, the patient should take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular schedule is to be resumed. A double dose must never be taken to make up for a missed tablet. The adult dosage guidelines are generally used for older patients.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tamoxifen Teva

This overview summarizes the research structure for Tamoxifen, describing the types of studies that have been conducted, the outcomes measured, and the recognized gaps in the evidence. This information is intended to describe the state of the research and does not contain any medical advice or treatment instructions.


Evidence for Use in Hormone-Sensitive Breast Cancer

Research exploring Tamoxifen for patients with hormone-sensitive breast cancer is extensive and primarily based on formal methods such as large-scale Randomized Controlled Trials (RCTs). The evidence was built through these RCTs and subsequent Meta-analyses that pool data from thousands of participants. These study types are widely used in research for observing long-term patterns in disease.

Researchers designed these studies to monitor crucial outcomes over extended periods. The main outcomes measured were end points such as the rate of Disease Recurrence, Overall Survival (OS), and Disease-Free Survival (DFS). Trials also monitored the development of Contralateral Breast Cancer. These studies included women both before menopause (premenopausal) and after menopause (postmenopausal), as well as men with the disease.

The findings describe patterns observed in the studies related to recurrence rates and survival measurements across a broad population. Scientific efforts continue to investigate tumors that do not respond (de novo resistance) or stop responding over time (acquired resistance). Research is ongoing to understand the role of genetic variations in patient outcomes.


Evidence for Use in Benign Hormonal Breast Enlargement (Gynecomastia)

The evidence base for Tamoxifen for benign hormonal breast enlargement in men is structured differently from that for breast cancer. This area has been explored using Systematic Reviews, Prospective Cohort Studies, and a collection of smaller controlled studies. The research primarily examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort (tenderness and pain), as well as measured reductions in the size of the enlarged tissue.

Studies explored short-term symptom changes in male adolescents and adult men. Findings for this indication were mixed across different small studies, particularly concerning the achievement of complete resolution of the mass size. However, research highlights measurements related to pain and tenderness in the observed populations during the study period.


Studies help show what has been observed so far in specific populations under specific conditions. Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (EBCTCG)
  2. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
  3. Label: tamoxifen citrate - Tamoxifen Citrate tablet (FDA Prescribing Information via DailyMed/NIH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tamoxifen Teva (FAQ)


Q: Is Tamoxifen Teva the same thing as Nolvadex?

A: The active substance in Tamoxifen Teva is tamoxifen. Nolvadex was the original brand name for a tablet containing the same active substance. Official documents confirm that Tamoxifen Teva contains the same active compound, but Teva refers to the specific company that manufactures and supplies this version of the medicine.


Q: Does Tamoxifen Teva cause weight gain?

A: Official safety documents list fluid retention and swelling in the arms and legs as common documented effects. Additionally, unusual weight gain or loss has been reported in regulatory sources, though its incidence may be lower than other documented effects.


Q: Is it true that Tamoxifen Teva can affect my periods?

A: Yes, official documents list menstrual irregularities (changes in pattern) and the absence of periods (amenorrhea) as reported effects, particularly in women who have not yet reached menopause. Vaginal bleeding or discharge is also officially documented as a very common side effect.


Q: Can men take Tamoxifen Teva?

A: Official eligibility profiles confirm that the medicine is generally approved for use in Adult Males for its authorized therapeutic purposes. This includes treatment for certain types of breast cancer as well as for some hormonal conditions.


Q: What are the long-term side effects of Tamoxifen Teva?

A: Regulatory safety information specifically notes that the development of endometrial cancer and certain changes to the eye, such as cataracts and optic neuropathy, are associated with long-term exposure to tamoxifen. These risks, as well as the risk of blood clots, are noted in official documents as serious safety concerns.


Q: Is it safe to drive while on Tamoxifen Teva?

A: Regulatory guidelines document that the medicine may cause effects such as dizziness, fatigue, or lightheadedness in some people. Documents suggest caution due to the potential for these effects, particularly before performing tasks that require alertness.


Q: Can Tamoxifen Teva cause joint pain?

A: Official adverse reaction reports document the occurrence of muscle, joint, or bone pain in some patients taking tamoxifen. This effect is documented in regulatory sources, though it is frequently noted in the adverse reaction data.


Q: Does Tamoxifen Teva affect fertility?

A: Tamoxifen is strictly contraindicated in pregnancy due to the potential for fetal harm. Regulatory guidance requires women of childbearing potential to use effective non-hormonal contraception during treatment and for a period after stopping, as the drug does not reliably cause infertility.


Q: Is it possible to be allergic to Tamoxifen Teva?

A: Yes. Use of the medicine is strictly contraindicated in patients with a known hypersensitivity (allergy) to the active substance, tamoxifen, or any of its other ingredients. Severe allergic reactions have been reported in official documents.


Q: Do I need regular blood tests while using Tamoxifen Teva?

A: Official prescribing information advises that periodic monitoring is important while taking this medicine. This monitoring can include checks of blood counts and liver function tests, which are part of the periodic monitoring suggested in prescribing information.


Q: Are there any specific supplements that should be avoided with Tamoxifen Teva?

A: Yes. The herbal product St. John’s Wort is officially documented to interact with tamoxifen and should be avoided, as it may reduce the drug's blood levels. It is recognized that discussing all supplements with a healthcare provider is important.


Q: Can I drink alcohol while taking Tamoxifen Teva?

A: Regulatory documents note that alcohol consumption may require limitation or avoidance. This caution is noted because alcohol consumption may decrease the medicine's efficacy or potentially worsen side effects like dizziness or lightheadedness.


Q: Does Tamoxifen Teva affect bone density?

A: Research indicates that in certain tissues like bone, the medicine can have an estrogen-like effect. For postmenopausal women, evidence describes this effect as being associated with slower bone loss; however, it may have different effects in premenopausal women.


Q: Will taking Tamoxifen Teva make me tired?

A: Fatigue is officially listed as a Very Common side effect in the regulatory safety profile for tamoxifen. This means that a noticeable number of patients in clinical studies reported feeling tired.


Q: Does Tamoxifen Teva affect sleep quality?

A: While regulatory documents do not directly list insomnia, very common documented side effects like hot flashes and night sweats are noted to potentially cause sleep disturbance. These hormonal side effects are frequently reported by patients.


Q: Does Tamoxifen Teva interact with common antidepressants?

A: Yes. Official drug interaction documents advise against co-administration with strong CYP2D6 Inhibitors. This class includes some common antidepressant medicines, as the combination may significantly reduce the concentration of the active form of tamoxifen in the body.


Q: Does Tamoxifen Teva interact with contraceptive pills?

A: Official regulatory guidance advises that hormonal contraceptives, including birth control pills, should not be used by women taking tamoxifen. This restriction is due to the potential for interference with the drug's action and the recognized risk of thromboembolic events.


Q: Can Tamoxifen Teva be taken by women who have gone through menopause?

A: Yes. Official eligibility criteria confirm that the medicine is generally approved for use in Adult Females who are postmenopausal (after menopause). Safety and side effect profiles are reviewed for both pre- and postmenopausal women.


Q: Are there any food restrictions when taking Tamoxifen Teva?

A: Regulatory documents state that Tamoxifen Teva tablets may be consumed with or without food. This means there are no specific restrictions on what you can eat or drink at the time you take the medicine.


Q: How does the evidence characterize the effect of Tamoxifen Teva on overall survival?

A: Research evidence, primarily from large-scale Randomized Controlled Trials, describes patterns related to overall survival (OS) measurements that were observed when compared to control groups. These findings are part of the research that supports the drug’s intended use.


Q: Are there different strengths of Tamoxifen Teva available?

A: Yes. Tamoxifen Teva is officially available as oral tablets in specific strengths, typically 10 mg and 20 mg.


Q: Does Tamoxifen Teva have any effect on cholesterol levels?

A: Studies have documented that tamoxifen may be associated with decreases in total cholesterol and LDL cholesterol (often called 'bad' cholesterol) levels. However, it has also been reported to cause increases in serum triglyceride levels.


Q: Can people with a history of deep vein thrombosis (DVT) use Tamoxifen Teva?

A: For women taking Tamoxifen Teva for the risk reduction setting (preventative use), a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) is a contraindication (a reason not to use the drug). The risk of recurrence is noted as a serious safety concern.


Q: Is it normal to feel anxious after starting Tamoxifen Teva?

A: Official documents list mood changes and depression as documented adverse reactions in clinical studies. While anxiety is not always explicitly listed, it falls within the category of central nervous system and mood effects reported in the safety data.


Q: What official documents say about Tamoxifen Teva's potential effect on vision?

A: Official safety documents list potential effects on vision, including the common occurrence of cataracts and the rare occurrence of optic neuropathy. Official documents describe the importance of discussing any changes in vision with a healthcare provider.


Q: Is Tamoxifen Teva associated with hot flashes?

A: Yes. Hot flashes are officially documented as a Very Common side effect in the regulatory safety profile. This means that a large percentage of patients in clinical studies have reported experiencing them.


Q: Does Tamoxifen Teva cause gastrointestinal issues like nausea?

A: Yes. Nausea is officially documented as a Very Common side effect in the regulatory safety profile. Other gastrointestinal issues have also been reported by patients in clinical study data.


Q: Why is the brand name Tamoxifen Teva important compared to just 'tamoxifen'?

A: Tamoxifen is the generic name of the active medicine, while Teva refers to the specific pharmaceutical company that manufactured and supplied this particular version. Both contain the same active ingredient, but the brand name distinguishes the supplier.

Advertisements

How should Tamoxifen Teva be stored and disposed of?

Storage and Protection

Tamoxifen Teva tablets must be stored at room temperature, typically between 15 C and 30 C (59 F and 86 F). The medication must be kept in a secure location that is protected from light, excessive heat, and moisture to maintain its stability. It is essential to keep the container closed and stored out of the reach and sight of children and pets.

Disposal Requirements

Tamoxifen is classified as a hazardous drug. Therefore, any unused, expired, or leftover portion, along with all contaminated materials, must be handled as regulated waste. To ensure safe disposal, do not flush this medication down a toilet or discard it in the regular trash. Unused or expired medication must be returned to a pharmacy or follow local Environment, Health & Safety (EHS) guidelines for proper hazardous waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tamoxifen Teva found in:

A-Z Index: